Cautious Hold Rating on AnaptysBio Amid Mixed Clinical Trial Results and Strategic Uncertainties

Analyst Emily Bodnar from H.C. Wainwright maintained a Hold rating on AnaptysBio (ANAB – Research Report) and keeping the price target at $22.00.

Emily Bodnar’s rating is based on the current data from AnaptysBio’s clinical trials, which show mixed results. The Phase 2a trial for rosnilimab demonstrated results that were comparable to peresolimab, but with some variability in patient responses. While rosnilimab showed potential for sustained or slightly improved responses, the data is not yet complete, with over 50% of patients still awaiting Week 28 results. Additionally, the company has indicated that it will not advance the rheumatoid arthritis program into Phase 3 without a partner, and is awaiting further data from other trials. This cautious approach suggests that while there is potential, there are also uncertainties that warrant a Hold rating. Emily Bodnar’s analysis reflects a balanced view of the potential and risks associated with AnaptysBio’s current clinical developments.